The Impact of Once-Nightly Versus Twice-Daily Dosing and Baseline Beliefs About HAART on Adherence to Efavirenz-Based HAART Over 48 Weeks: The NOCTE Study.

Cooper, V., Horne, R., Gellaitry, G., Vrijens, B., Lange, A.C., Fisher, M. and White, D. (2010) The Impact of Once-Nightly Versus Twice-Daily Dosing and Baseline Beliefs About HAART on Adherence to Efavirenz-Based HAART Over 48 Weeks: The NOCTE Study. JAIDS: Journal of Acquired Immune Deficiency Syndromes, 53 (3). pp. 369-377. 10.1097/QAI.0b013e3181ccb762.

Full text not available from this repository.

DOI: 10.1097/QAI.0b013e3181ccb762


Item Type:Article
Departments, units and centres:Department of Practice and Policy > Centre for Behavioural Medicine
ID Code:1648
Journal or Publication Title:JAIDS: Journal of Acquired Immune Deficiency Syndromes
Deposited By:Library Staff
Deposited On:09 Jul 2010 10:32
Last Modified:20 Oct 2011 15:10

Repository Staff Only: Item control page

School of Pharmacy Staff Only: Edit a copy to replace this item